BiomX CEO to Present at H.C. Wainwright 27th Annual Global Investment Conference

Core Insights - BiomX Inc. will present positive topline results from its Phase 2 trial evaluating BX211 for the treatment of Diabetic Foot Osteomyelitis (DFO) at the H.C. Wainwright 27th Annual Global Investment Conference [1][2] Company Overview - BiomX is a clinical-stage company focused on developing natural and engineered phage therapies targeting specific pathogenic bacteria for chronic diseases with significant unmet needs [4] - The company utilizes its BOLT platform to customize phage compositions against proprietary bacterial targets [4] Product Details - BX211 is a phage treatment specifically designed for DFO associated with Staphylococcus aureus, a bacterial infection that can lead to amputation in diabetic patients [3] - The Phase 2 trial results indicated that BX211 was safe and well-tolerated, with a statistically significant reduction in ulcer size (p = 0.046 at week 12; p = 0.052 at week 13) and a difference greater than 40% from placebo by week 10 [3] - Statistically significant improvements were also observed in ulcer depth (p = 0.048) and reduction of ulcer area expansion (p = 0.017) over the 12-week treatment period [3] Future Plans - BiomX is planning a registrational trial for BX211, pending discussions and feedback from the FDA [3]